Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.33 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.33 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20928290 | 0.85 | EPHX1 (0.65) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL23200480 | 0.82 | EPHX1 (0.70) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL14424470 | 0.80 | EPHX1 (0.73) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL8243750 | 0.79 | GAA (0.63) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL104271 | 0.78 | EPHX1 (0.58) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL23274129 | 0.77 | EPHX1 (0.54) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL24507087 | 0.76 | EPHX1 (0.64) | EPHX1ALDH1A1KMT2AKDM4E | |
| SCHEMBL22134964 | 0.76 | EPHX1 (0.66) | EPHX1GAABCHENAAAACHE | |
| SCHEMBL15777906 | 0.75 | EPHX1 (0.89) | EPHX1GAABCHENAAAALDH1A1 | |
| SCHEMBL2801495 | 0.74 | EPHX1 (0.69) | EPHX1GAABCHENAAAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4048315-B1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS INC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240238430-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238430-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4048314-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048315-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125891-A2 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125908-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125884-A1 | IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125904-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125915-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238430-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | CA14, CA12, CA13 | EPHX1 689/4885GAA 253/4885BCHE 50/4885 |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885BCHE 260/4885 |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885BCHE 260/4885 |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885BCHE 260/4885 |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | EPHX2, FAAH2, CYP8B1 | EPHX1 5/4885GAA 1173/4885BCHE 118/4885 |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | HTR3D, PNMT, HTR3B | EPHX1 764/4885GAA 3886/4885BCHE 1437/4885 |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885BCHE 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.